ABG
VIR icon

Ally Bridge Group’s Vir Biotechnology VIR Stock Holding History

Ally Bridge Group’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-275,000
Closed -$7.37M – 35
2020
Q4 		$7.37M Buy
+275,000
New +$8.94M 1.26% 22

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.57B AUM 15.23% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Ally Bridge Group's VIR Position: Q1 2021 in Review

Ally Bridge Group sold out of Vir Biotechnology (VIR) in Q1 2021, closing a stake of 275,000 shares — an estimated $7.37M sold.

Ally Bridge Group first reported a position in VIR in Q4 2020 and held it in 1 quarter. The position peaked at $7.37M in Q4 2020. 157 funds tracked by Wall St. Rank hold VIR as of Q1 2021.

  • Ally Bridge Group reported no remaining Vir Biotechnology position as of Q1 2021 after selling out during the quarter.
  • Ally Bridge Group sold 275,000 Vir Biotechnology shares in Q1 2021, an estimated $7.37M.
  • Ally Bridge Group first reported a position in Vir Biotechnology in Q4 2020 and held it in 1 quarter.
  • Ally Bridge Group's Vir Biotechnology position peaked at $7.37M in Q4 2020.
  • 157 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2021.

Based on Ally Bridge Group's 13F filing for Q1 2021, filed 17 May 2021.